// App-Quantinova.ai

TPS4601 : SAMETA An open-label, three-arm, multicenter, phase III study of savolitinib + durvalumab versus sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma (PRCC).

Researchers

Presenter

  • Toni K. Choueiri

Principal Investigators

  • Wanning Xu

  • Lynne Poole

  • Aino Telaranta-Keerie

  • Ryan Hartmaier

  • Thomas Powles

Medical Centers

  • Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

  • Oncology Late Development, Oncology R&D, AstraZeneca, New York, NY

  • Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, United Kingdom

  • Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Urology

  • Nephrology

  • Oncology (ONC)

Disease

  • Renal cell carcinoma

  • Metastatic Renal Cell Cancer

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Savolitinib

  • Durvalumab

  • Sunitinib

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multiple Arm

  • Multinational

  • Multicenteric

Phase

  • III

Study Id's

  • NCT05043090

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved